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In addition to being a structural protein that packages the viral genomic RNA, hepatitis C virus (HCV) core protein
possesses regulatory functions. In this report, we demonstrate that the HCV core protein could enhance the gene
transactivation activity of the tumor suppressor p53, regardless of whether p53 was derived from an exogenous or an
endogenous gene. The activation of p53 by the HCV core protein was supported by the observation that the HCV core protein
could enhance the expression of p21waf1/Cip1, a downstream effector gene of p53, in a p53-dependent manner. Further studies
indicated that the HCV core protein could also suppress hepatocellular growth via p53. The HCV core protein and p53 could
bind to each other in vitro, which was evidenced by the coimmunoprecipitation, the GST pull-down, and the Far-Western blot
assays. The deletion-mapping analysis indicated that the carboxy-terminal sequence of p53 located between amino acids
366 and 380 was required for the core protein binding. These results raised the possibility that the HCV core protein might
activate p53 through direct physical interaction. The persistent perturbation of p53 activity by the HCV core protein during
chronic infection may have important consequences in HCV pathogenesis. © 1999 Academic Press
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eINTRODUCTION
Approximately 85% of people infected by hepatitis C
irus (HCV) will become chronic carriers. Many of
hese patients will develop severe liver diseases
ithin two decades of infection and will require liver
ransplantation for survival. Chronic infection by HCV
s also associated with an increased risk of liver can-
er. Despite its clinical importance, how HCV interacts
ith its host to cause liver diseases remains largely
nknown.
HCV is a positive-stranded RNA virus with a genome
ize of about 9.6 kb. This RNA genome contains a long
pen reading frame that codes for a polyprotein with a
ength of 3010 amino acids. This polyprotein is pro-
essed by cellular and viral proteases to generate at
east 10 viral gene products. The HCV core protein is
ocated at the amino terminus of the polyprotein se-
uence. This protein is the viral capsid protein (Yasui
t al., 1998). It is separated from the following E1
nvelope protein by a signal peptidase located in the
umen of the endoplasmic reticulum (Liu et al., 1997).
he core protein can remain associated with the E1
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134nvelope protein by noncovalent bonds, possibly for
he formation of the mature virion (Lo et al., 1996).
The full-length HCV core protein is 191 amino acids
n length. It can also be cleaved between amino acids
73 and 174 to generate a truncated core protein (Lo et
l., 1996; Yasui et al., 1998). Both the full-length and the
runcated core proteins are associated primarily with
he ER membrane (Lo et al., 1995; Yasui et al., 1998),
lthough the truncated core protein has also been
etected in the nucleus (Liu et al., 1997). In addition to
eing the viral capsid protein, the HCV core protein
as been shown to possess a number of regulatory
unctions. It can suppress or enhance apoptosis (Ray
t al., 1996b; Ruggieri et al., 1997; Zhu et al., 1998), can
ctivate or suppress the expression of viral and cellu-
ar genes (Ray et al., 1995, 1997; Shih et al., 1995), and
ay be oncogenic (Chang et al., 1998; Kawamura et
l., 1997; Moriya et al., 1998; Pasquinelli et al., 1997;
ay et al., 1996a). Recent studies indicate that it can
uppress the activation of the transcription factor
F-kB by inhibiting the degradation of IkBa, and it can
ctivate the transcription factor AP-1 by activating the
NK and MAPK pathways (Shrivastava et al., 1998).
In order to understand its regulatory functions in HCV
athogenesis, we studied whether the HCV core protein
ould interact with p53, an important tumor suppressor.
ur results indicated that the HCV core protein could
ctivate both exogenous and endogenous p53. It could
lso activate the expression of p21waf1/Cip1, a downstream
ffector of p53, and suppress hepatocellular growth in a
53-dependent manner.
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135ACTIVATION OF p53 TUMOR SUPPRESSOR BY HCVRESULTS AND DISCUSSION
ctivation of p53 by HCV core protein
In order to investigate whether the HCV core protein
an functionally interact with p53, we performed tran-
ient transfection studies using p53-negative Hep3B
epatoma cells (Bressac et al., 1990). POST2CAT is a
eporter plasmid that contains the chloramphenicol
cetyltransferase (CAT) coding sequence. In this plas-
id, the expression of CAT is under the control of two
andem copies of the p53 binding site and the minimal
romoter of the thymidine kinase (tk) gene of the herpes
implex virus (Hachiya et al., 1994). As shown in Fig. 1A,
he CAT activity expressed by the POST2CAT plasmid
as increased approximately 10-fold in the presence of
he p53-expressing plasmid pCMV–p53. In contrast, the
AT activity expressed from pBLCAT2, the parental plas-
id of POST2CAT that lacks the p53 binding site
Hachiya et al., 1994), was not affected by p53 (data not
hown; also see below). These results indicated that p53
ould stimulate the expression of CAT through its binding
ites in POST2CAT and were consistent with what had
een reported before (Hachiya et al., 1994). As shown in
ig. 1A, the CAT expression induced by p53 was further
ncreased nearly 3-fold in the presence of the HCV core
rotein plasmid pCDEF-RC. As the HCV core protein by
tself could not activate the expression of the CAT re-
orter (Fig. 1A), these results indicated that the HCV core
rotein could enhance the gene transactivation activity of
53.
The above experiments were conducted using the
53-expressing plasmid. To investigate whether the HCV
FIG. 1. Regulation of p53 transactivation activity by the HCV core p
otransfected into cells with pCMV–p53 or the pRc/CMV control vector
ere lysed for the CAT assay. pXGH5, a control reporter plasmid that
xperiments for monitoring the transfection efficiency. All the results we
CDEF) to generate the relative CAT activity. (B) Studies conducted in He
he control pCDEF expression vector (open bar) or the core protein-exp
esults were normalized against the control (i.e., cells cotransfected wi
hown in (A) and (B) represent the average of at least three different eore protein could exert the same effect on the endog- pnous p53, similar experiments were conducted using
epG2 cells, a well-differentiated hepatoblastoma cell
ine that expresses the wild-type p53 (Bressac et al.,
990; Muller et al., 1997). As shown in Fig. 1B, POST2CAT
xpressed 20-fold more CAT activity than pBLCAT2, in-
icating that the endogenous p53 in HepG2 cells could
timulate gene expression through the p53 binding sites.
he CAT activity expressed by POST2CAT but not by
BLCAT2 was further increased approximately 3-fold by
he core protein. Thus, the results shown in Fig. 1B were
onsistent with those shown in Fig. 1A and indicated that
he HCV core protein could also enhance the gene trans-
ctivation activity of the endogenous p53 in HepG2 cells.
ctivation of p21waf1/Cip1 by HCV core protein
hrough a p53-dependent pathway
If the HCV core protein could indeed enhance the
ene transactivation activity of p53, then it should be
ble to enhance the expression of the downstream ef-
ector genes of p53 in a p53-dependent manner. Since
he sequence of the p53 binding site in the POST2CAT
eporter was derived from the promoter of the p21waf1/Cip1
ene (Hachiya et al., 1994), we investigated whether the
CV core protein could interact with p53 to activate the
xpression of p21waf1/Cip1. Hep3B cells were transfected
ith the p53-expressing plasmid, the HCV core protein-
xpressing plasmid, or both. pXGH5, a plasmid that ex-
resses the human growth hormone (hGH), was also
ncluded in all the transfection experiments to serve as
n internal control to monitor the transfection efficiency.
ells were lysed 2 days after transfection, and the ex-
(A) Studies conducted in Hep3B cells. The POST2CAT reporter was
DEF–RC or the pCDEF vector. Forty-eight hours after transfection, cells
ses the human growth hormone, was included in all the transfection
alized against the control (i.e., cells cotransfected with pRc/CMV and
lls. The POST2CAT or pBLCAT2 reporter was cotransfected with either
plasmid pCDEF–RC (solid bar) into HepG2 cells. Similar to (A), all the
T2CAT and pCDEF) to generate the relative CAT activities. The results
ents.rotein.
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136 LU ET AL.21waf1/Cip1 were analyzed by Western blot using their
espective antibodies. As shown in Fig. 2A, the expres-
ion level of hGH was not significantly different in differ-
nt samples, indicating similar transfection efficiencies.
he expression of p21waf1/Cip1 in Hep3B cells was not
etectable in the absence of p53 (lane 1). However, its
xpression was activated in the presence of p53 (lane 2).
n agreement with the results shown in Fig. 1, this acti-
ation of p21waf1/Cip1 expression by p53 was further in-
reased approximately threefold by the HCV core protein
lane 4). Similar to the results shown in Fig. 1, the ability
f the HCV core protein to stimulate the expression of
21waf1/Cip1 was p53-dependent, as the HCV core protein
y itself could not stimulate the expression of p21waf1/Cip1
lane 3).
A similar experiment was also conducted using HepG2
ells to investigate whether the HCV core protein could
ctivate the expression of p21waf1/Cip1 through the endoge-
ous p53. As there is a high basal level of p21waf1/Cip1 ex-
ression in HepG2 cells due to the presence of the endog-
nous p53, it was necessary to establish stable transfor-
ants that expressed the core protein. As shown in Fig. 2B,
he HCV core protein increased the expression level of
21waf1/Cip1 slightly more than twofold in HepG2 cells without
ignificantly affecting the p53 protein level. This particular
esult was obtained using a mixture of more than 100 stable
ell clones. Similar results were obtained when three ran-
om cell colonies that expressed the core protein were
nalyzed individually (data not shown).
The finding that HepG2 cells stably expressing the
CV core protein had an increased level of p21waf1/Cip1
as also consistent with the observation that the HCV
FIG. 2. Activation of p21waf1/Cip1 expression by the HCV core protein.
A) Western-blot analysis of p21waf1/Cip1 expression in Hep3B cells. Lane
, cells transfected with pRc/CMV and pCDEF vectors; lane 2, cells
ransfected with pCMV–p53 and pCDEF; lane 3, cells transfected with
Rc/CMV and pCDEF–RC; and lane 4, cells transfected with pCMV–p53
nd pCDEF–RC. pXGH5 was included in all the transfection experi-
ents to monitor the transfection efficiency. (B) Western-blot analysis of
21waf1/Cip1 expression in HepG2 cells. Lane 1, stable HepG2 cells
ransfected by the control pCDEF vector; lane 2, stable HepG2 cells
ransfected by pCDEF–RC. The locations of p53, the HCV core protein,
nd p21waf1/Cip1 are indicated. The asterisk indicates the location of a
onspecific band, which serves as a loading control.ore protein could activate the endogenous p53. Thus, pur results provide an explanation for the frequent ele-
ation of p21waf1/Cip1 expression in the hepatocytes of
hronic HCV patients (Crary and Albercht, 1998). Ray et
l. (1997, 1998) reported that the HCV core protein could
uppress the promoters of p53 and p21waf1/Cip1 genes.
herefore, their results were inconsistent with ours. We
elieve it is important to confirm the reported results by
nalyzing the expression of the endogenous genes. As
learly demonstrated in Fig. 2, the HCV core protein
ncreased rather than suppressed the expression of the
21waf1/Cip1 gene.
uppression of cell growth by HCV core protein
n a p53-dependent manner
p21waf1/Cip1 is a cdk inhibitor and its increased expres-
ion can often suppress the cell cycle (Ko and Prives,
996). The ability of the HCV core protein to stimulate the
xpression of p21waf1/Cip1 in a p53-dependent manner
aises the possibility that the HCV core protein might
lso be able to suppress cell growth in a p53-dependent
anner. To investigate this possibility, we conducted the
olony formation assay based on the rationale that the
uppression of cell growth should result in the reduction
f colony numbers. The p53-expressing plasmid pMTne-
wtp53, which carried the neomycin-resistant gene, or
ts control vector pMTneo was cotransfected with the
CV core protein-expressing plasmid pCDEFDneo-RC or
ts parental expression vector pCDEFDneo into Hep3B
ells. The plasmid pXGH5, which expresses hGH under
he control of metallothionein (MT) promoter, was used to
onitor the transfection efficiency. Cells were then se-
ected with the neomycin analog G418 and the colony
umbers were counted 2 to 3 weeks later. As shown in
ig. 3, cells transfected with pMTneowtp53 produced
lightly less than half the number of colonies as those
ransfected with pMTneo, indicating that p53 could sup-
ress the growth of Hep3B cells. The colony number was
urther reduced to about 20% when cells were cotrans-
ected with pMTneowtp53 and the core protein-express-
ng plasmid pCDEFDneo-RC. Since the core protein by
tself did not reduce the colony numbers (Fig. 3), this
esult indicated that the core protein could suppress
ep3B cell growth in a p53-dependent manner.
In the experiment shown in Fig. 3, the expression of
53 was controlled by the MT promoter, which is a weak
romoter in the absence of its metal inducers (Searle et
l., 1985). Similar results were obtained when this weak
T promoter was replaced with the strong immediate
arly promoter of cytomegalovirus (CMV), although in the
atter case, the number of colonies produced by cells
ransfected with the p53 plasmid was reduced to about
% of the control (data not shown).
Thus, the results shown in Fig. 3 indicated that the
ore protein could suppress Hep3B cell growth in a
53-dependent manner. Friedman et al. (1997) and
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137ACTIVATION OF p53 TUMOR SUPPRESSOR BY HCVonchel et al. (1994) reported conflicting results regard-
ng whether p53 could suppress the growth of Hep3B
ells. The former reported negative results and the latter
eported positive results. Our results were consistent
ith those of Ponchel et al. This may be because Fried-
an et al. analyzed the transient effect of p53 on Hep3B
ells, whereas We and Ponchel analyzed the stable ef-
ect of p53 on these cells.
A similar experiment was also conducted using
epG2 cells, which express wild-type p53 from its en-
ogenous gene. In this case, the core protein-expressing
lasmid pCDEF-RC and its control vector pCDEF, which
oth contained the neomycin-resistant gene, were sep-
rately transfected into HepG2 cells. The cell colonies
ere then selected with G418. In contrast to the suppres-
ion seen in Hep3B cells, no reduction of the colony
umber by the core protein was detected. HepG2 cells
xpress the wild-type p53 and a high basal level of
21waf1/Cip1 but yet have a high proliferation rate. This
uggests that p53 and p21waf1/Cip1 do not suppress HepG2
ell growth. Indeed, Jiang et al. (1996) reported that the
verexpression of exogenous p53 in HepG2 cells did not
ffect the cell cycle but did sensitize cells to chemically
nduced apoptosis. It is conceivable that other mecha-
isms might have been developed to antagonize the p53-
nd p21waf1/Cip1-mediated cell growth arrest during the
ncogenesis of HepG2 cells.
hysical interaction between HCV core protein
nd p53
Although our results demonstrated that the HCV core
rotein could activate p53, the mechanism of this acti-
ation remains unclear. The HCV core protein may acti-
ate p53 through the signal transduction pathways, as it
FIG. 3. Colony formation assay for cell growth analysis. Cells were tr
tained with Giemsa stain to facilitate colony counting. Control, ce
MTneowtp53 and pCDEFDneo; core, cells transfected with pMTneo
CDEFDneo–RC. (A) The representative staining result of a set of trans
he results shown represent the average of four different transfectionas been shown to be involved in these pathways (Shri- aastava et al., 1998; Zhu et al., 1998). Alternatively, the
CV core protein may activate p53 by direct physical
nteraction. To investigate the latter possibility, we per-
ormed coimmunoprecipitation experiments. The HCV
ore protein, either full-length or truncated at amino acid
51, was synthesized and radiolabeled with [35S]methi-
nine in vitro using the rabbit reticulocyte lysates and
lasmid pCMV-RC or pCMV-RC151. These proteins were
mmunoprecipitated with a mouse monoclonal antibody
irected against p53 either in the presence or in the
bsence of p53. As shown in Fig. 4A, both the full-length
nd the truncated core proteins could be immunoprecipi-
ed with DNA plasmids and cell colonies were selected with G418 and
sfected with pMTneo and pCDEFDneo; p53, cells transfected with
DEFDneo–RC; core 1 p53, cells transfected with pMTneowtp53 and
cells. (B) The relative colony numbers normalized against the control.
ents.
FIG. 4. Interaction between p53 and HCV core proteins. (A) The
oimmunoprecipitation experiment. [35S]Methionine-labeled HCV core
roteins were synthesized using the rabbit reticulocyte lysates (lanes 1
nd 4) and immunoprecipitated with the anti-p53 antibody in the pres-
nce of E. coli lysates with (lanes 2 and 5) or without p53 (lanes 3 and
). Lanes 1–3, the 21-kDa full-length HCV core protein; lanes 4–6, the
CV core protein truncated at amino acid 151. (B) The GST pull-down
xperiment. Lanes 1 and 4, the 35S-labeled HCV core proteins synthe-
ized in vitro; lanes 2 and 5, the pull-down experiment conducted using
he GST–p53 fusion protein; lanes 3 and 6, the pull-down experiment
onducted using the control GST protein. Lanes 1–3, the full-length
CV core protein; lanes 4–6, the HCV core protein truncated at aminoansfect
lls tran
and pC
fectedcid 151.
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138 LU ET AL.ated by the anti-p53 antibody in the presence but not in
he absence of p53. This result suggests that the HCV
ore protein can bind to p53 and that this binding does
ot require the HCV core protein sequence located
ownstream of amino acid 151.
To ensure that the HCV core protein can indeed bind
o p53, a different experiment using a fusion protein
erived from glutathione S-transferase (GST) and p53
as also conducted. The [35S]methionine-labeled HCV
ore protein was incubated with either the GST–p53
usion protein or the GST control protein and then pre-
ipitated with the glutathione–Sepharose 4B beads. As
hown in Fig. 4B, the full-length and the truncated HCV
ore proteins could be pulled down specifically by the
ST–p53 fusion protein but not by the GST control pro-
ein. These results confirmed the results shown in Fig.
A and indicate that the HCV core proteins can bind to
53 and that this binding does not require the carboxy-
erminal sequence of the core protein.
equirement of the carboxy terminus of p53
or binding by the HCV core protein
A deletion-mapping experiment was subsequently
erformed to identify the p53 sequence that interacts
ith the HCV core protein. Different p53 deletion mutants
ere expressed in Escherichia coli using the pET3a
xpression vector and subsequently purified by gel elec-
rophoresis. The purified p53 proteins are shown in Fig.
A. A separate gel identical to the one shown in Fig. 5A
as Western-blotted to nitrocellulose membrane and in-
ubated with the full-length HCV–RH core protein that
ad also been expressed in E. coli. After incubation, the
embrane was successively incubated with a rabbit
ntibody directed against the core protein and an alka-
ine phosphatase-conjugated goat anti-rabbit secondary
ntibody. The binding signal was then developed with
he Bio-Rad AP-substrate kit. As shown in Fig. 5B, the
FIG. 5. Deletion-mapping analyses for the p53 sequence required fo
urified p53 proteins; (B and D) the Far-Western blot results of the gelruncation of the amino-terminal sequence of p53 up to wmino acid 160 had no effect on the binding of the core
rotein. However, the deletion of the carboxy-terminal
equence downstream of amino acid 342 abolished the
inding by the core protein. This result indicates that the
arboxy-terminal sequence, but not the amino-terminal
equence, of p53 is important for binding by the HCV
ore protein. To further characterize the core protein
inding sequence in the carboxy terminus of p53, an-
ther set of deletion-mapping experiments was per-
ormed. The purified p53 mutants truncated at various
ocations in the carboxy terminus are shown in Fig. 5C,
nd the Far-Western blot results are shown in Fig. 5D.
he truncation of p53 at amino acid 380 did not affect the
inding of the core protein. However, the truncation of
53 at amino acid 366 or further upstream resulted in the
oss of the binding signal, indicating that the p53 se-
uence located between amino acid 366 and 380 is
mportant for binding by the HCV core protein. The bind-
ng results shown in Fig. 5 were specific, as the signals
ould be removed by preincubating the primary antibody
ith the E. coli lysate containing the HCV core protein
ut not with the control E. coli lysate (data not shown).
As p53 was denatured prior to gel electrophoresis
uring the deletion-mapping analysis, the results shown
n Fig. 5 indicate that the core protein likely recognized a
inear epitope in p53. This linear epitope most likely
ncompasses the p53 sequence located between amino
cids 366 and 380. Interestingly, acetylation or binding by
he monoclonal antibody PAb421 to the vicinity of this
equence has been shown to result in a conformational
hange and the activation of p53 (Gu and Roeder, 1997;
o and Prives, 1996). It is tempting to speculate that the
CV core protein binds to the p53 sequence located
etween amino acids 366 and 380 and that this binding
lters the conformation of p53 to either directly activate
53 or indirectly activate p53 by rendering it more sus-
eptible to acetylation, phosphorylation, or interaction
g by the HCV core protein. (A and C) Coomassie blue staining of the
n in (A) and (C), respectively.r bindinith other cellular proteins. It appears unlikely that the
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139ACTIVATION OF p53 TUMOR SUPPRESSOR BY HCVCV core protein stays associated with p53 to activate
ene expression, because little of the core protein was
etected in the nucleus and instead some of p53 was
ocalized with the core protein to the cytoplasm in a
onfocal microscopy study (data not shown). However,
s the attempt to perform the coimmunoprecipitation
ssay using cells cotransfected with the p53-expressing
lasmid and the core protein-expressing plasmid has not
een successful, further studies will be required to pro-
ide definitive proof that the HCV core protein indeed
ctivates p53 in cells through direct physical interaction.
Our studies add the HCV core protein to the growing
ist of viral proteins that regulate p53 activity. The HCV
ore protein is unusual, as it is the only viral structural
rotein known to possess such activity. The functions of
he interaction between the core protein and p53 in the
ife cycle of HCV remain unclear. Since the activation of
53 can lead to apoptosis (Ko and Prives, 1996; Muller et
l., 1997), this interaction may represent a cellular de-
ense mechanism to eliminate viral infection by sensitiz-
ng HCV infected cells to apoptosis. In this regard, it is
nteresting to note that it has been demonstrated that the
CV core protein can sensitize cells to fas-mediated
poptosis (Ruggieri et al., 1997). Although it is somewhat
ontroversial, recent studies suggest that the HCV core
rotein may be oncogenic (Chang et al., 1998; Kawamura
t al., 1997; Moriya et al., 1998; Pasquinelli et al., 1997;
ay et al., 1996a). If this is indeed correct, then the HCV
ore protein would possess two opposite activities: one
o suppress hepatocellular growth and the other to trans-
orm cells. These activities of the HCV core protein are
eminiscent of ras and myc oncogenes. Ras can trans-
orm immortalized cells and can also activate p53 and
21waf1/Cip1 expression to induce senescence in primary
ells (Serrano et al., 1997), and myc can promote cell
rowth and can also suppress cell growth by sensitizing
ells to apoptosis (Thompson, 1998). It would be inter-
sting to examine whether the oncogenic potential of the
CV core protein is enhanced in a p53-negative back-
round such as in a p53-knockout mouse.
Finally, our finding that the HCV core protein has the
otential to suppress hepatocellular growth in a p53-
ependent manner has important implications in HCV
athogenesis. The inefficient regeneration of hepato-
ytes caused by the core protein during chronic HCV
nfection may enhance the accumulation of stellate cells
nd fibrosis in liver (French, 1996) and facilitate the
evelopment of liver cirrhosis in HCV patients.
MATERIALS AND METHODS
onstruction of plasmids
The construction of the pET-RC and pCMV-RC plas-
ids has been described before (Lo et al., 1995). The
onstruction of pCMV-RC151 was identical to that of
CMV-RC except that codon 152 of the core gene se- tuence in this plasmid was converted to a termination
odon. Hence, this plasmid expresses a truncated core
rotein with a length of 151 amino acids. pCDEF-RC was
onstructed by inserting the core gene of the HCV-RH
solate (Lo et al., 1995) into the HindIII and EcoRI sites of
he pCDEF vector (Kim et al., 1993; a gift of Dr. Tatsuo
iyamura). In this plasmid, the expression of the HCV
ore protein was under the control of the eIF-1a gene
romoter. pCDEFDneo and pCDEFDneo-RC were con-
tructed by deleting the sequence between MscI and
srII sites in the neomycin-resistant gene of pCDEF and
CDEF-RC, respectively. Hence, pCDEFDneo and
CDEFDneo-RC lack the neomycin gene of their parental
lasmids. The DNA plasmids containing various trun-
ated p53 sequences were constructed by using similar
CR cloning procedures and the pET-3a vector (Wu et al.,
anuscript in preparation). The expression of HCV core
roteins in E. coli BL21(DE3)pLysS strain has been de-
cribed in detail before (Lo et al., 1995; Lo and Ou, 1998).
he expression of p53 in E. coli was conducted using the
ame procedures. pGEX2T–p53 contains the p53 se-
uence fused to the GST sequence. This GST–p53 fusion
rotein was expressed in E. coli DH5a strain following
he manufacturer’s procedures (AMRAD Corp.). For in
itro translation, the HCV core protein RNAs were syn-
hesized from pCMV-RC and pCMV-RC151 using the T7
NA polymerase after the linearization of the plasmids
ith XbaI. The HCV core proteins were synthesized from
hese RNAs and radiolabeled with [35S]methionine using
he rabbit reticulocyte lysates (Promega). In POST2CAT,
he expression of chloramphenicol acetyltransferase is
nder the control of two tandem copies of the p53 bind-
ng site and the minimal promoter of the tk gene of the
erpes simplex virus (Hachiya et al., 1994). pBLCAT2 is
he parental plasmid of POST2CAT that lacks the p53
inding site (Hachiya et al., 1994). The constructions of
MTneowtp53 and pCMV–p53 will be described else-
here (Wu et al., in preparation).
NA transfection and the CAT assay
Hep3B and HepG2 cells were maintained in Dul-
ecco’s modified Eagle’s medium containing 10% fetal
ovine serum. Hep3B cells growing in a 60-mm dish
ere transfected with a mixture of the following plasmids
sing the calcium phosphate precipitation method: 2 mg
OST2CAT reporter or pBLCAT2 control, 10 ng pCMV–
53 or pRc/CMV control (Invitrogen), 8 mg pCDEF-RC
ore protein-expressing plasmid or its parental pCDEF
ector, and 0.4 mg pXGH5 (Nichols Diagnostic) for ex-
ressing hGH for monitoring the transfection efficiency.
he expression of hGH in pXGH5 was regulated by the
etallothionein promoter. HepG2 cells growing in a
0-mm dish were transfected with a mixture of the fol-
owing plasmids using the calcium phosphate precipita-
ion method: 2 mg POST2CAT reporter or pBLCAT2 con-
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140 LU ET AL.rol, 6 mg pCDEF-RC core protein-expressing plasmid or
CDEF vector, 0.4 mg pXGH5, and 1.6 mg pUC19. Two
ays after transfection, the medium was harvested and
nalyzed for hGH activity using a commercial radioim-
unoassay kit (Nichols Diagnostic), and the cells were
ysed for the CAT assay using our previous procedures
Guo et al., 1991). In our pilot experiments, we observed
hat the CAT activities increased as the amount of
CDEF-RC was increased in the cotransfection experi-
ent. The CAT activity reached a plateau when the
mount of pCDEF–RC reached 4 mg. Therefore, for a
0-mm dish, 6–8 mg pCDEF was routinely used in the
otransfection studies.
estern-blot analysis for p21waf1/Cip1 expression
Hep3B cells growing in a 100-mm dish were trans-
ected with a mixture of the following plasmids: 2 mg
CMV–p53 or pRc/CMV vector, 12 mg pCDEF-RC or
CDEF vector, 5 mg pUC19, and 0.5 mg pXGH5 for ex-
ressing hGH for monitoring the transfection efficiency.
orty-eight hours after transfection, cells were scraped
ff the dish in Tris-buffered saline (TBS; 10 mM Tris–HCl,
50 mM NaCl). After a brief centrifugation at 1500 g, the
ell pellet was resuspended in TBS containing 0.1% Non-
det P-40 (NP40) and sonicated. The cell lysates were
hen spun in a microcentrifuge at full speed for two min.
he protein concentration in the supernatant was mea-
ured using the Bio-Rad protein assay kit. The same
mount of protein of each sample was then subjected to
lectrophoresis in a 12.5% SDS–PAGE gel and Western-
lotted. The pairs of primary and secondary antibodies
sed were mouse anti-p53 monoclonal antibodies (a
:1:1 mixture of PAB421, PAB1801, and PAB-DO-1; Onco-
ene Sciences) and alkaline phosphatase (AP)-conju-
ated goat anti-mouse antibody (Boehringer Mannheim),
abbit anti-HCV core antibody (Lo et al., 1995) and AP-
onjugated goat anti-rabbit antibody (Bio-Rad), rabbit
nti-p21waf1/Cip1 antibody (Santa Cruz Biochemicals) and
orseradish peroxidase-conjugated goat anti-rabbit anti-
ody (Pierce), and rabbit anti-hGH antibody (Yeh and Ou,
991) and HRP-conjugated goat anti-rabbit antibody. The
RP-conjugated secondary antibody was selected for
21waf1/Cip1 and hGH because it allowed us to conduct the
hemiluminescence assay to increase the sensitivity for the
etection of these two proteins. Stable HepG2 cells that
xpressed the HCV core protein were established by trans-
ecting a 60-mm dish of cells with 10 mg pCDEF–RC, fol-
owed by selection with the neomycin analog G418 at a
oncentration of 400 mg/ml for 2 to 3 weeks. The cell
olonies selected were either pooled or isolated individu-
lly and further expanded. HepG2 cells transfected with the
ontrol pCDEF vector were simultaneously selected to
erve as the control. eolony formation assay.
Hep3B cells growing in a 60-mm dish were transfected
ith 2 mg pMTneowtp53 or pMTneo vector, 8 mg
CDEFDneo–RC or pCDEFDneo vector, and 0.5 mg
XGH5 for monitoring the transfection efficiency. The
NA plasmids were transfected using the calcium phos-
hate precipitation method. The second day after trans-
ection, cells were trypsinized and replated into a
00-mm dish. Forty hours after transfection, the neomy-
in analog G418 was added into the medium to a final
oncentration of 400 mg/ml. Cell colonies became ap-
arent 2 to 3 weeks after selection. They were fixed in
00% methanol, stained with Giemsa stain for 1 h at room
emperature, rinsed briefly in water, and then counted.
iemsa stain was prepared by dissolving 1 g of the solid
owder (Sigma) in 66 ml glycerol at 60°C for 2 h. After the
reparation had cooled to room temperature, 66 ml
ethanol was added. A quantity of 2.5 ml of this stock
olution was then mixed with 3 ml methanol and 100 ml
ater for staining cell colonies. The colony formation
ssay for HepG2 cells was conducted the same way,
xcept that 10 mg pCDEF–RC or pCDEF vector was used
or the transfection.
oimmunoprecipitation and GST pull-down analyses
Two microliters of the translational mixture containing
he [35S]methionine-labeled core protein was mixed with 5
l E. coli lysates with or without p53 and then diluted in 1
l TBS containing 0.5% NP40. After incubation at room
emperature for 1 h, 1 ml monoclonal antibody against p53
PAb1801, Oncogene Sciences) was added and the mixture
as further incubated at 4°C for 1 h. The immunocomplex
as precipitated with 15 ml Pansorbin (Calbiochem), and
he precipitated products were analyzed on a 12.5% SDS–
AGE gel. The GST pull-down experiment was conducted
ollowing the manufacturer’s procedures (Pharmacia Bio-
ech). Briefly, 10 ml E. coli lysates containing GST or the
ST–p53 fusion protein was incubated with 30 ml glutathi-
ne–Sepharose 4B gel slurry in 1 ml phosphate-buffered
aline (PBS) containing 1% Triton X-100 at room tempera-
ure for 1 h and then the precipitated complex was washed
ith PBS. After the suspension of the precipitates in 300 ml
BS plus 0.5% NP40, 3 ml of the in vitro translational mixture
ontaining [35S]methionine-labeled core protein was added
nd the mixture was incubated at room temperature for 1 h.
he precipitated products were analyzed on a 12.5% SDS–
AGE gel.
he Far–Western blot analysis
The E. coli lysates containing various p53 deletion mu-
ants were subjected to gel electrophoresis. The p53 pro-
ein bands were purified from the gel after a brief staining in
.2% Coomassie brilliant blue 250. These proteins were
luted in PBS containing 0.1% sodium dodecyl sulfate and
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141ACTIVATION OF p53 TUMOR SUPPRESSOR BY HCVsed for the Far-Western blot analysis. Ten micrograms of
ach of the p53 proteins was subjected to electrophoresis
n a 10% gel and Western-blotted to nitrocellulose mem-
rane. The membrane was preblocked in TBS containing
% nonfat milk for 3 h at 4°C, hybridized to the same
locking solution containing 1 mg/ml HCV core protein that
ad been gel-purified, washed once in TBS and twice in
BS containing 0.1% NP40, and then hybridized to the rabbit
nti-core antibody (Lo et al., 1995). The secondary antibody
sed was alkaline phosphatase-conjugated goat anti-rabbit
ntibody, and the signals were developed using the Bio-
ad AP color kit.
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